Ciprofloxacin targets bacterial DNA gyrase and topoisomerase IV, enzymes vital for bacterial DNA replication, transcription, repair, and recombination. This inhibition disrupts the bacterial cell’s ability to properly replicate its genetic material, leading to cell death.
Specifically, ciprofloxacin binds to these enzymes, preventing them from supercoiling and unwinding DNA. This blockage halts DNA replication, ultimately causing bacterial growth cessation and bacterial cell death. The drug’s effectiveness hinges on its ability to penetrate the bacterial cell wall and reach its intracellular targets.
Common otitis media pathogens, like Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, are susceptible to ciprofloxacin’s mechanism. However, resistance is a growing concern, so susceptibility testing is crucial before treatment.
The concentration of ciprofloxacin needed to inhibit bacterial growth varies depending on the specific bacterial species and its resistance profile. Higher concentrations are often required for resistant strains.
